02.07.23 -- How BMS Uses AI To Improve Study Design And Reduce Costs

In 2022, Bristol Myers Squibb (BMS) announced plans to work with AI developer Owkin to design and optimize cardiovascular drug trials. In this Q&A, Venkat Sethuraman, SVP, global biometrics and data sciences at BMS, discusses the partnership, the use of AI in cardiovascular trials, and how the technology will create a better patient experience.

Delve into an illustration of how robust EDC systems fully support the operational requirements introduced by the decision to leverage eSource data.

Dive into six insights to stay on top of the rapidly shifting research industry and to ensure your research organization doesn’t get left behind. 

Read about how remote data collection and telehealth practices have paved the way for more flexible clinical trial designs that collect data from sources beyond research site locations.

More than 80 percent of sites surveyed want to get paid in 30 days, and many clinical technology companies offer specialized software solutions to address the site payments process. However, these systems still require a large effort by the sponsor to operate. What is the secret sauce for success?

Patients are even more digital-savvy and exposed to sophisticated technology. This presents a huge opportunity to incorporate patient engagement into clinical trials and elevate patient engagement efforts in ongoing clinical trials.

See how a modern eTMF system built with a new exchange standard promises to bring better collaboration and compliance.

At Cenduit, we never try to fit cell and gene therapy studies — or any kind of study — into predefined functionality. The Cenduit IRT and Quantum Interactive™ agile design platforms and reporting tools support clients’ most complex requirements.